C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4)
- The report reviews C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) Overview 10
Therapeutics Development 11
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Stage of Development 11
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Therapy Area 12
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Indication 13
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Companies 19
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Universities/Institutes 24
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Therapeutics Assessment 26
Assessment by Monotherapy/Combination Products 26
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Companies Involved in Therapeutics Development 33
AdAlta Pty Ltd. 33
Ambrx, Inc. 34
Anchor Therapeutics, Inc. 35
Biokine Therapeutics Ltd. 36
BioLineRx, Ltd. 37
Bristol-Myers Squibb Company 38
Eli Lilly and Company 39
Globavir Biosciences, Inc. 40
GlycoMimetics, Inc. 41
NeED Pharma s.r.l. 42
Pharis Biotec GmbH 43
Polyphor Ltd. 44
Sanofi 45
TaiGen Biotechnology Co., Ltd. 46
Upsher-Smith Laboratories, Inc. 47
X4 Pharmaceuticals, Inc. 48
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Drug Profiles 49
(filgrastim + plerixafor) - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ALB-408 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
AM-3114 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ATI-2341 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
balixafortide - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BKT-170 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BL-8040 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
burixafor - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
GBV-4086 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
GMI-1359 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
hz-515H7 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
LY-2510924 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
ND-4043 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
plerixafor - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
POL-5551 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Protein to Inhibit CXCR4 for Inflammation - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
PTX-9908 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Q-122 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Recombinant Protein to Agonize CXCR4 for Multiple Sclerosis - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules to Activate CXCR4 for Immunology and Oncology - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
ulocuplumab - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
USL-311 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
X-4P001 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
X-4P002 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Dormant Projects 96
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Discontinued Products 101
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Featured News & Press Releases 102
May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359 102
May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 102
May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 102
May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 103
Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 103
Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting 104
Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML 105
Mar 23, 2016: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment 107
Mar 17, 2016: GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016 108
Dec 14, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment 108
Dec 14, 2015: X4 Pharmaceuticals Announces FDA Allowance of X4P-001 IND for Phase 1b/2a Study of in Refractory Clear Cell Renal Cell Carcinoma 109
Dec 14, 2015: X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing 110
Dec 07, 2015: GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model 112
Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions 112
Nov 09, 2015: GlycoMimetics To Present Poster on GMI-1359 at  at 57th Annual ASH Meeting 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Comparative Analysis by Unknown Stage Development, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Development by Companies, H1 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Products under Investigation by Universities/Institutes, H1 2016 25
Assessment by Monotherapy/Combination Products, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Pipeline by AdAlta Pty Ltd., H1 2016 33
Pipeline by Ambrx, Inc., H1 2016 34
Pipeline by Anchor Therapeutics, Inc., H1 2016 35
Pipeline by Biokine Therapeutics Ltd., H1 2016 36
Pipeline by BioLineRx, Ltd., H1 2016 37
Pipeline by Bristol-Myers Squibb Company, H1 2016 38
Pipeline by Eli Lilly and Company, H1 2016 39
Pipeline by Globavir Biosciences, Inc., H1 2016 40
Pipeline by GlycoMimetics, Inc., H1 2016 41
Pipeline by NeED Pharma s.r.l., H1 2016 42
Pipeline by Pharis Biotec GmbH, H1 2016 43
Pipeline by Polyphor Ltd., H1 2016 44
Pipeline by Sanofi, H1 2016 45
Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 46
Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 47
Pipeline by X4 Pharmaceuticals, Inc., H1 2016 48
Dormant Projects, H1 2016 96
Dormant Projects (Contd..1), H1 2016 97
Dormant Projects (Contd..2), H1 2016 98
Dormant Projects (Contd..3), H1 2016 99
Dormant Projects (Contd..4), H1 2016 100
Discontinued Products, H1 2016 101